[go: up one dir, main page]

ZA9610792B - Stabilized pharmaceutical composition - Google Patents

Stabilized pharmaceutical composition

Info

Publication number
ZA9610792B
ZA9610792B ZA9610792A ZA9610792A ZA9610792B ZA 9610792 B ZA9610792 B ZA 9610792B ZA 9610792 A ZA9610792 A ZA 9610792A ZA 9610792 A ZA9610792 A ZA 9610792A ZA 9610792 B ZA9610792 B ZA 9610792B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
stabilized pharmaceutical
composition
quinolin
fluorophenyl
Prior art date
Application number
ZA9610792A
Other languages
English (en)
Inventor
Thoyojiro Muramatsu
Katsumi Mashita
Yasuo Shinoda
Hironori Sassa
Hiroyuki Kawashima
Yoshio Tanizawa
Hideatu Takeuchi
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Publication of ZA9610792B publication Critical patent/ZA9610792B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9610792A 1995-12-22 1996-12-20 Stabilized pharmaceutical composition ZA9610792B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35465495 1995-12-22

Publications (1)

Publication Number Publication Date
ZA9610792B true ZA9610792B (en) 1997-07-09

Family

ID=18439011

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610792A ZA9610792B (en) 1995-12-22 1996-12-20 Stabilized pharmaceutical composition

Country Status (26)

Country Link
EP (1) EP0814782B1 (fr)
JP (1) JP3276962B2 (fr)
KR (1) KR100348842B1 (fr)
CN (1) CN1137684C (fr)
AT (1) ATE228354T1 (fr)
AU (1) AU725622B2 (fr)
CA (1) CA2213608C (fr)
CZ (1) CZ288545B6 (fr)
DE (2) DE122011000014I1 (fr)
DK (1) DK0814782T3 (fr)
ES (1) ES2183023T3 (fr)
FR (1) FR11C0007I2 (fr)
HU (1) HU227798B1 (fr)
IL (1) IL121565A (fr)
MX (1) MX9706389A (fr)
NO (2) NO316724B1 (fr)
NZ (1) NZ324446A (fr)
PL (1) PL186907B1 (fr)
PT (1) PT814782E (fr)
RU (1) RU2142790C1 (fr)
SI (1) SI0814782T1 (fr)
SK (1) SK282991B6 (fr)
TW (1) TW436294B (fr)
UA (1) UA29513C2 (fr)
WO (1) WO1997023200A1 (fr)
ZA (1) ZA9610792B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
EP1036563A1 (fr) * 1999-03-08 2000-09-20 MERCK & CO. INC. Formulations retard a usage oral de simvastatine sous forme ouverte d'acide dihydroxy, de ses sels ou de ses esters
WO2000053173A1 (fr) * 1999-03-08 2000-09-14 Merck & Co., Inc. Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
JP4048780B2 (ja) 1999-12-13 2008-02-20 株式会社豊田中央研究所 キノリン誘導体化合物及び有機電界発光素子
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
DE60008608T2 (de) * 2000-06-09 2004-12-30 Lek Pharmaceutical And Chemical Co. D.D. Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
PT1429802E (pt) * 2001-09-28 2013-01-24 Tntgamble Inc Sistema de entrega para componente biológico
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AU2003264443A1 (en) * 2002-09-20 2004-04-08 Kowa Co., Ltd. Preparation for external use
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2005062824A2 (fr) 2003-12-23 2005-07-14 Merck & Co., Inc. Composes anti-hypercholesterolemie
JPWO2005063294A1 (ja) 2003-12-30 2007-12-13 興和株式会社 γ−セクレターゼ複合体形成阻害剤
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
EP1719525B1 (fr) 2004-02-25 2014-12-10 Kowa Company, Ltd. Promoteur de transfert nuclaire pour la proteine cdc42 et methode de criblage pour celle-ci
WO2005079846A1 (fr) 2004-02-25 2005-09-01 Kowa Company, Ltd. AGENT PROMOTEUR DE TRANSFERT NUCLÉAIRE POUR LA PROTÉINE Rac ET MÉTHODE POUR LA CRIBLER
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US20080194548A1 (en) 2005-01-06 2008-08-14 Forrest Michael J Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders
EP1726962A1 (fr) * 2005-05-24 2006-11-29 Leiden University Medical Center Concentrations plasmatiques de lipoprotéine E pour surveiller et réduire le risque des maladies cardiovasculaires
CN101103983B (zh) * 2006-07-14 2012-09-26 海南盛科生命科学研究院 一种用碱试剂稳定的含匹伐他汀钙的药用组合物及制备工艺
EP2170065A4 (fr) 2007-06-20 2011-11-23 Merck Sharp & Dohme Alcanes diphényl-substitués
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
WO2012046772A1 (fr) 2010-10-06 2012-04-12 国立大学法人東京大学 Médicament destiné à la prévention et au traitement d'un lymphœdème
EP2665707B1 (fr) 2011-01-20 2017-01-18 Merck Sharp & Dohme Corp. Antagonistes du récepteur des minéralocorticoïdes
WO2012141160A1 (fr) * 2011-04-12 2012-10-18 沢井製薬株式会社 Préparation contenant de la pitavastatine et son procédé de production
EP2697203B1 (fr) 2011-04-13 2017-05-24 Merck Sharp & Dohme Corporation Antagonistes des récepteurs de minéralocorticoïdes
WO2012153181A1 (fr) 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique comprenant de la pitavastatine ou ses sels pharmaceutiquement acceptables
CN102861018A (zh) * 2011-07-05 2013-01-09 南京长澳医药科技有限公司 一种匹伐他汀钙制剂及其制备工艺
JP5809467B2 (ja) * 2011-07-12 2015-11-11 エルメッド エーザイ株式会社 ピタバスタチン含有組成物及びその製造方法
JP5844574B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する安定化された薬物組成物
US9505730B2 (en) 2011-10-13 2016-11-29 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP3269362A1 (fr) 2012-08-08 2018-01-17 KOWA Co., Ltd. Composition pharmaceutique comprenant de la pitavastatine
CN102885797A (zh) * 2012-10-29 2013-01-23 福州海王福药制药有限公司 一种含匹伐他汀钙的组合物及其制备方法和应用
US9750723B2 (en) 2013-10-31 2017-09-05 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
JP6649902B2 (ja) 2014-05-30 2020-02-19 ファイザー・インク 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
CN106659714B (zh) 2014-07-18 2021-06-08 俄亥俄大学 用于改变生物信号传导的咪唑和噻唑组合物
CN105343008A (zh) * 2015-12-15 2016-02-24 青岛华之草医药科技有限公司 一种匹伐他汀钙组合物
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (fr) * 1986-02-13 1994-02-15 Tadashi Makino Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production
CA1336714C (fr) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Mevalonolactone de type quinoleine utilisee comme inhibiteurs de la biosynthese du cholesterol
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
EP0814782B1 (fr) 2002-11-27
KR19980702370A (ko) 1998-07-15
IL121565A0 (en) 1998-02-08
NO316724B1 (no) 2004-04-19
PL186907B1 (pl) 2004-03-31
TW436294B (en) 2001-05-28
HUP9903536A2 (hu) 2000-03-28
CA2213608A1 (fr) 1997-07-03
SI0814782T1 (en) 2003-04-30
EP0814782A1 (fr) 1998-01-07
FR11C0007I1 (fr) 2011-04-22
IL121565A (en) 2002-02-10
DK0814782T3 (da) 2002-12-16
NO973814D0 (no) 1997-08-19
SK282991B6 (sk) 2003-01-09
PL321868A1 (en) 1997-12-22
KR100348842B1 (ko) 2002-12-31
PT814782E (pt) 2003-04-30
ATE228354T1 (de) 2002-12-15
DE69625046D1 (de) 2003-01-09
HU227798B1 (en) 2012-03-28
NO2011006I1 (no) 2011-06-06
DE69625046T2 (de) 2003-04-10
SK116097A3 (en) 1998-03-04
UA29513C2 (uk) 2000-11-15
RU2142790C1 (ru) 1999-12-20
JPH11503763A (ja) 1999-03-30
CN1189098A (zh) 1998-07-29
DE122011000014I1 (de) 2011-11-03
CZ268197A3 (cs) 1998-05-13
NO2011006I2 (no) 2012-10-01
NZ324446A (en) 1999-08-30
HUP9903536A3 (en) 2001-06-28
AU725622B2 (en) 2000-10-19
JP3276962B2 (ja) 2002-04-22
ES2183023T3 (es) 2003-03-16
AU1171597A (en) 1997-07-17
CN1137684C (zh) 2004-02-11
FR11C0007I2 (fr) 2012-03-16
MX9706389A (es) 1998-08-30
NO973814L (no) 1997-10-13
CZ288545B6 (cs) 2001-07-11
CA2213608C (fr) 2003-07-08
WO1997023200A1 (fr) 1997-07-03

Similar Documents

Publication Publication Date Title
ZA9610792B (en) Stabilized pharmaceutical composition
RU92004564A (ru) Фармацевтические композиции и способ их получения
DE3574020D1 (en) Stable salts of sam with polyanions
AU2681300A (en) Solid oral dosage form containing an enhancer
CA2057291A1 (fr) Compositions pharmaceutiques de calcitonine humaine stable
EP0208519A3 (fr) Composition solubilisée d'un agent pharmaceutique peu soluble
CA2023563A1 (fr) Preparation pharmaceutique injectable stable d'acide folique et de sels de leucovorine et methode de production
HRP20030002A2 (en) STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE
WO2002000615A3 (fr) Procede d'isolation de lovastatine
NZ337798A (en) Pharmaceutical compositions containing lamivudine
MY103079A (en) New ophtalmological composition of matter
CA2244389A1 (fr) Preparation pharmaceutique de cilansetron stabilisee contre la racemisation
EP0397147A3 (fr) Solutions stables de dérivés de la rebeccamycine et leur préparation
EP0403303A3 (fr) Composition pour le traitement des cheveux
CO5070673A1 (es) Composiciones farmaceuticas en forma de solucion estable que comprenden (1s,4r)-cis-4-(2-amino-6-(ciclopropilamino)-9h -purin-9-il)-2-ciclopenteno-1-metanol, un quelador de metal y un agente endulzante
BG99197A (en) Means for the treatment of cataract and method for its preparation
KR910014122A (ko) 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
CA2075926A1 (fr) Esters d'acides amines et d'hydroquinone, methodes d'obtention et compositions phramaceutiques ou cosmetiques qui en contiennent
ES8403719A1 (es) "un metodo para preparar una suspension acuosa estabilizada de oxendolona".
AU6243094A (en) Stable aqueous acid compositions thickened with polyacrylamide
AU5635496A (en) Derivatives of 2,3:4,6-di-o-isopropylidene-alpha-l-xylo-2-he xulofluranosonic acid
AU1970695A (en) Stable strongly acidic aqueous compositions containing persulfate salts
AU3964500A (en) Aqueous cosmetic preparation containing tartaric acid esters or citric acid esters of alkyl polyglucose, and vitamins
AU7308296A (en) Stabilised pharmaceutical compositions containing dobutamine
ES8308927A1 (es) Procedimiento para la preparacion de 3-(5'- ribonucleotidos) de compuestos del tipo de lincomicina y clindamicina.